Sorry. You can not access the page.

The page pro.biontech.com is not accessible from your location. You have been redirected to our corporate website for more information and resources.

Advancing science to transform medicine

BioNTech is a global biopharmaceutical company pioneering novel investigative therapies for cancer and infectious diseases. We are committed to transforming how cancer is treated. With more than 15 years of immunology and technological expertise, our ambition is to develop medicines that work together to treat cancer from multiple angles – training the immune system to recognize cancer more effectively, addressing multiple disease drivers, and targeting tumor cells with precision.

Our diversified portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates. These complementary modalities are designed to address the full spectrum of cancer, from early-stage disease with high risk of recurrence to advanced and metastatic cancers. 

We are advancing science to deliver tomorrow’s breakthroughs today.

Our vision and mission

We are dedicated to translating science into survival by harnessing the potential of the human immune system to improve the health of people worldwide through innovative immunotherapies and vaccines targeting cancer and infectious diseases.

Learn more

Our history

Explore BioNTech’s journey from a small startup to a global biotechnology company dedicated to ushering in a new era of medicine with combination therapies based on novel therapeutic approaches.

Learn more

Annual report 

Reflecting on the achievements of 2025, our guiding motto for this year’s annual report, “Momentum”, encapsulates the progress that defined the past year for us: We achieved key milestones that strengthened our position in oncology, validated our approaches with encouraging data, and set the stage for significant progress in 2026. Read more about those milestones in our report.

Download the 2025 annual report

18 MB / PDF

Explore more about BioNTech